Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan
In Vivo. 2019 Nov-Dec;33(6):2249-2254. doi: 10.21873/invivo.11730.
BACKGROUND/AIM: In this study, we assessed the safety and efficacy of combination therapy with S-1, oxaliplatin and leucovorin (SOL) in advanced esophageal squamous cell carcinoma (ESCC) patients.
Ten unresectable or recurrence ESCC patients, who had been previously treated with more than two regimens were included in this study. The treatment schedule comprised S-1 40-60 mg and fixed dose of leucovorin 25 mg together orally twice a day for one week, followed by one-week of rest. Oxaliplatin 85 mg/m was given as an intravenous infusion on day one, repeated every two weeks.
Of the eight patients with measurable lesions, two patients with partial response (25%) and two with stable disease (25%) were observed. Disease control rate was 50%. Median progression-free survival and overall survival were 5.0 and 9.3 months, respectively. The main common adverse events were malaise (60%), decreased appetite (50%), peripheral sensory neuropathy (40%).
SOL therapy showed promising antitumor activity with acceptable toxicity even for heavily pretreated ESCC.
背景/目的：本研究评估了 S-1、奥沙利铂和亚叶酸（SOL）联合治疗在晚期食管鳞状细胞癌（ESCC）患者中的安全性和疗效。
本研究纳入了 10 例不可切除或复发的 ESCC 患者，这些患者之前接受了超过两种方案的治疗。治疗方案包括 S-1 40-60 mg 和固定剂量的亚叶酸 25 mg，每天口服两次，持续一周，然后休息一周。奥沙利铂 85 mg/m 作为静脉滴注，在第一天使用，每两周重复一次。
在 8 例可测量病灶的患者中，有 2 例患者观察到部分缓解（25%）和 2 例患者疾病稳定（25%）。疾病控制率为 50%。中位无进展生存期和总生存期分别为 5.0 个月和 9.3 个月。主要的常见不良反应为乏力（60%）、食欲下降（50%）、周围感觉神经病变（40%）。
即使是经过大量预处理的 ESCC，SOL 治疗也显示出有希望的抗肿瘤活性和可接受的毒性。
